Hologic — Nov 4, 2024 release

“Looking ahead to fiscal 2025, our robust balance sheet and projected strong cash flows provide exceptional operational flexibility, positioning us well to achieve sustainable revenue growth and even faster EPS growth over the long term.” Hologic’s financial guidance for the first quarter and full year 2025 is shown in the table below.  The guidance is based on a full year non-GAAP tax rate of approximately 19.5%, and diluted shares outstanding of approximately 235 million for the full year.  Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2025 as in fiscal 2024.  Organic revenue guidance for fiscal 2025 is in constant currency and excludes the divested Blood Screening and SSI ultrasound imaging businesses.  Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition.  Organic revenue excluding COVID-19 is in constant currency and is organic revenue excluding COVID-19 assay revenue, COVID-19 related revenue, and discontinued product sales in Diagnostics. The guidance below includes the financial results of the closed Endomagnetics acquisition for the full year, which will become organic in the fourth quarter of fiscal 2025, but does not include any contribution from the Gynesonics acquisition, which has not closed.  There is no year over year net selling day impact comparing 2025 to 2024.  First quarter and full year fiscal 2025 guidance incorporates the expected impact from the ongoing temporary stop-ship of Horizon DXA systems (Skeletal).     Current Guidance       Guidance $   Reported % Increase